These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7037265)

  • 1. Captopril kinetics.
    Duchin KL; Singhvi SM; Willard DA; Migdalof BH; McKinstry DN
    Clin Pharmacol Ther; 1982 Apr; 31(4):452-8. PubMed ID: 7037265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of captopril in normal subjects.
    Kripalani KJ; McKinstry DN; Singhvi SM; Willard DA; Vukovich RA; Migdalof BH
    Clin Pharmacol Ther; 1980 May; 27(5):636-41. PubMed ID: 6989546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal handling of captopril: effect of probenecid.
    Sinhvi SM; Duchin KL; Willard DA; McKinstry DN; Migdalof BH
    Clin Pharmacol Ther; 1982 Aug; 32(2):182-9. PubMed ID: 7047044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of captopril in dogs and monkeys.
    Singhvi SM; Peterson AE; Ross JJ; Shaw JM; Keim GR; Migdalof BH
    J Pharm Sci; 1981 Oct; 70(10):1108-12. PubMed ID: 7028947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases.
    Duchin KL; McKinstry DN; Cohen AI; Migdalof BH
    Clin Pharmacokinet; 1988 Apr; 14(4):241-59. PubMed ID: 3292102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of food on the bioavailability of captopril in healthy subjects.
    Singhvi SM; McKinstry DN; Shaw JM; Willard DA; Migdalof BH
    J Clin Pharmacol; 1982; 22(2-3):135-40. PubMed ID: 7040498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet.
    Singhvi SM; Kripalani KJ; Dean AV; Keim GR; Kulesza JS; Meeker FS; Ross JJ; Shaw JM; Migdalof BH
    J Pharm Sci; 1981 Aug; 70(8):885-8. PubMed ID: 7031222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Captopril kinetics in chronic congestive heart failure.
    Cody RJ; Schaer GL; Covit AB; Pondolfino K; Williams G
    Clin Pharmacol Ther; 1982 Dec; 32(6):721-6. PubMed ID: 6754211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Captopril disulfide conjugates may act as prodrugs: disposition of the disulfide dimer of captopril in the rat.
    Drummer OH; Jarrott B
    Biochem Pharmacol; 1984 Nov; 33(22):3567-71. PubMed ID: 6095854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.
    Straehl P; Galeazzi RL; Soliva M
    Clin Pharmacol Ther; 1984 Oct; 36(4):485-92. PubMed ID: 6478734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of renal insufficiency on the pharmacokinetics of captopril and converting enzyme inhibition in the hypertensive patient].
    Richer C; Chaignon M; Giroux B; Guédon J; Giudicelli JF
    Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1216-9. PubMed ID: 6098233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Captopril: pharmacology, metabolism and disposition.
    Migdalof BH; Antonaccio MJ; McKinstry DN; Singhvi SM; Lan SJ; Egli P; Kripalani KJ
    Drug Metab Rev; 1984; 15(4):841-69. PubMed ID: 6437780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients.
    Giudicelli JF; Chaignon M; Richer C; Giroux B; Guedon J
    Br J Clin Pharmacol; 1984 Nov; 18(5):749-58. PubMed ID: 6095887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure.
    Onoyama K; Hirakata H; Iseki K; Fujimi S; Omae T; Kobayashi M; Kawahara Y
    Hypertension; 1981; 3(4):456-9. PubMed ID: 7030952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impairment of captopril bioavailability by concomitant food and antacid intake.
    Mäntylä R; Männistö PT; Vuorela A; Sundberg S; Ottoila P
    Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):626-9. PubMed ID: 6389377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics and absolute bioavailability of atenolol.
    Mason WD; Winer N; Kochak G; Cohen I; Bell R
    Clin Pharmacol Ther; 1979 Apr; 25(4):408-15. PubMed ID: 428185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute bioavailability of chlorthalidone in man: a cross-over study after intravenous and oral administration.
    Fleuren HL; Thien TA; Verwey-van Wissen CP; van Rossum JM
    Eur J Clin Pharmacol; 1979 Feb; 15(1):35-50. PubMed ID: 421727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of zofenopril calcium in healthy subjects.
    Singhvi SM; Foley JE; Willard DA; Morrison RA
    J Pharm Sci; 1990 Nov; 79(11):970-3. PubMed ID: 2292772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination kinetics of captopril in patients with renal failure.
    Duchin KL; Pierides AM; Heald A; Singhvi SM; Rommel AJ
    Kidney Int; 1984 Jun; 25(6):942-7. PubMed ID: 6381858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.